【レポートの概要（一部）】
1. Report Overview
1.1 Multiple Sclerosis Drugs Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Multiple Sclerosis
2.1 What is Multiple Sclerosis?
2.1.1 Key Statistics: 2.5 Million Sufferers in the World
2.2 The Pathology of MS
2.2.1 Symptoms
2.3 Diagnosis of MS
2.3.1 Tests for MS Include These Technologies
2.4 Measuring MS
2.5 The Different Types of MS
2.5.1 Relapsing-Remitting MS (RRMS)
2.5.2 Secondary Progressive MS
2.5.3 Progressive Relapsing MS
2.5.4 Primary Progressive MS
2.5.5 Other Presentations of the Disease
2.6 Possible Causational Factors for MS
2.6.1 Genetic Factors
2.6.2 Infection
2.6.3 Environmental Factors and Less Well-Supported Theories
2.7 Demographics and Geographical Distribution
2.8 Different Treatments for MS
3. Leading Multiple Sclerosis Drugs
3.1 Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
3.1.1 First Non-Interferon Immunomodulator
3.1.2 Teva and the Approval of Generic Competition
3.1.3 The First Generic is Approved – Sandoz’s Glatopa
3.1.4 Industry Surprised by Copaxone’s Solid Sales, Despite Generic Competition: 40mg Dose is Key
3.1.5 Patents on Copaxone 40mg Being Contested – Although Teva Receives Good News in Europe
3.1.6 Copaxone Revenues 2011-2015
3.1.7 Copaxone Revenue Forecast 2016-2026
3.2 Tecfidera (dimethyl fumarate) by Biogen
3.2.1 Rapidly Grown Since 2013 to Become the Leading Oral MS Therapy
3.2.2 Tecfidera Revenues 2013-2015
3.2.3 Tecfidera Revenue Forecast 2016-2026
3.3 Avonex (interferon beta-1a) by Biogen
3.3.1 The Leading Interferon Therapy
3.3.2 Avonex Revenues 2011-2015
3.3.3 Patent Extension to 2026
3.3.4 Avonex Revenue Forecast 2016-2026
3.4 Gilenya (fingolimod) by Novartis
3.4.1 The First Oral Disease-Modifying Drug for MS
3.4.2 US Patent Trial and Appeal Board Sides Against Novartis
3.4.3 Gilenya Revenues 2011-2015
3.4.4 Gilenya Revenue Forecast 2016-2026
3.5 Rebif (interferon beta-1a) by Merck KGaA
3.5.1 Merck Attempting to Differentiate Rebif from Other Interferon Therapies
3.5.2 Rebif Revenues 2011-2015
3.5.3 Rebif Revenue Forecast 2016-2026
3.6 Tysabri (natalizumab) by Biogen
3.6.1 High Efficacy Offsets the Risks
3.6.2 Tysabri Revenues 2011-2015
3.6.3 Tysabri Revenue Forecast 2016-2026
3.7 Betaseron / Betaferon (interferon beta-1b) by Bayer
3.7.1 First Disease Modifying Drug for MS
3.7.2 Betaseron Revenues 2011-2015
3.7.3 Betaseron Revenue Forecast 2016-2026
3.8 Aubagio (teriflunomide) by Sanofi
3.8.1 More than 48,000 Patients Treated
3.8.2 Aubagio Revenues 2014-Q1 2016
3.8.3 Aubagio Revenue Forecast 2016-2026
3.9 Plegridy (peginterferon beta-1a) by Biogen
3.9.1 36% Reduction in ARR compared to Placebo
3.9.2 Plegridy Revenues 2014-2015
3.9.3 Plegridy Revenue Forecast 2016-2026
3.10 Lemtrada (alemtuzumab) by Sanofi
3.10.1 Very Effective, but with Side Effects
3.10.2 Lemtrada Past Revenues and Revenue Forecast 2016-2026
4. Multiple Sclerosis Drugs Pipeline 2016-2026
4.1 Ocrelizumab (Ocrevus / RG1594) by Roche
4.1.1 Humanised mAb Targeting CD20
4.1.2 First Drug to Receive Breakthrough Therapy Designation for MS
4.1.3 Exciting Latest Results from Two Phase 3 Trials
4.1.4 Ongoing Clinical Trials
4.1.5 Ocrelizumab Revenue Forecast 2016-2026
4.2 Ozanimod by Celgene
4.2.1 S1PR Modulator
4.2.2 Promising Results from Phase 2 RADIANCE Study
4.2.3 Ongoing Clinical Trials
4.2.4 Ozanimod in MS Revenue Forecast 2018-2026
4.3 Zinbryta (daclizumab high-yield process) by Biogen and AbbVie
4.3.1 Humanised mAb Being Jointly Developed by two Giants
4.3.2 Positive Opinion on Marketing Authorisation from the CHMP
4.3.3 Zinbryta Revenue Forecast 2016-2026
4.4 Ofatumumab by Novartis
4.4.1 Novartis Acquires Full Remaining Rights in $1bn Agreement
4.4.2 Advantages and Disadvantages over Ocrelizumab
4.5 Ponesimod by Actelion
4.5.1 S1PR Modulator
4.5.2 Positive Earlier Results
4.6 Laquinimod by Teva and Active Biotech
4.6.1 Troubled Oral Immunomodulator
4.6.2 Turned Down for European Licence
4.7 MED1003 by MedDay
4.7.1 Unique Method of Action
4.7.2 Results from MS-SPI and MS-ON
4.8 Masitinib by AB Science: Phase 3 and has Completed a Futility Analysis
4.9 Siponimod (BAF312) by Novartis: Competitor for Gilenya
5. Global Multiple Sclerosis Drugs Market 2016-2026
5.1 Global Multiple Sclerosis Drugs Market Forecast 2016-2026
5.2 What Factors Will Drive Growth in the Global MS Drugs Market?
5.2.1 Growth of Existing Products, Reaching Peak Blockbuster Revenues before Patent Expiry
5.2.2 Exciting New Products Due to be Launched Within the Next Ten Years
5.2.3 Premium Prices, Accompanied by Price Increases
5.2.4 Prevalence and Incidence of Multiple Sclerosis is Increasing
5.2.5 Unmet Needs and Strategic Partnering
5.3 What Factors will Restrain Growth in the Global MS Drugs Market?
5.3.1 Multiple Patent Expiries on Leading Drugs will Lead to Generic and Biosimilar Competition
5.3.2 Declining Healthcare Budgets Could Lead to Cost Pressures
5.3.3 Crowded Marketplace
6. Leading Therapeutic Segments: Revenue Prospects, 2016-2026
6.1 The Main Therapeutic Segments within the MS Drugs Market, Forecast 2016-2026
6.2 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.3 Monoclonal Antibodies Segment Forecast 2016-2026
6.4 S1PR Modulator Segment Forecast 2016-2026
6.5 Interferons Segment Forecast 2016-2026
6.6 Other Immunomodulators Segment Forecast 2016-2026
6.7 ‘Others’ Segment Forecast 2016-2026
7. National Markets for MS Drugs: Revenue Prospects, 2016-2026
7.1 Multiple Sclerosis Cases and Prevalence Values
7.2 Leading Regional Markets Forecast 2016-2026
7.2.1 Regional Composition of the Market in 2015, 2020 and 2026
7.3 US MS Drugs Market
7.3.1 Reasons why the US Market Dominates the MS Drugs Market to Such an Extent
7.3.2 Undergoing Some Changes
7.3.3 US MS Drugs Market Forecast 2016-2026
7.4 EU5 MS Drugs Market 2016-2026
7.4.1 Common Characteristics of all the EU5 Nations in Regards to MS Drugs and Drivers of Growth
7.4.2 German MS Drugs Market: Leading EU Market
7.4.2.1 German MS Drugs Market Forecast 2016-2026
7.4.3 French MS Drugs Market: Strong Healthcare System
7.4.3.1 French MS Drugs Market Forecast 2016-2026
7.4.4 UK MS Drugs Market
7.4.4.1 UK MS Drugs Market Forecast 2016-2026
7.4.5 Italian MS Drugs Market
7.4.5.1 Italian MS Drugs Market Forecast 2016-2026
7.4.6 Spanish MS Drugs Market
7.4.6.1 Spanish MS Drugs Market Forecast 2016-2026
7.5 Canadian MS Drugs Market: Country has Highest Rate of MS in the World
7.5.1 Canadian MS Drugs Market Forecast 2016-2026
7.6 Japanese MS Drugs Market Forecast 2016-2026
7.7 Chinese MS Drugs Market Forecast 2016-2026
7.8 Indian MS Drugs Market Forecast 2016-2026
8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change?
8.3 How will National Markets Develop from 2016 to 2026?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：多発性硬化症治療薬の世界市場および研究開発展望2016-2026■ 英文：Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026
■ 発行日：2016年6月
■ 調査会社：visiongain
■ 商品コード：VGAIN60619
■ 調査対象地域：グローバル
- 動物用抗感染薬の世界市場2015-2022According to Stratistics MRC, the Veterinary Anti-infectives market is accounted for $4.79 billion in 2015 and is expected to reach $9.11 billion by 2022 growing at a CAGR of 9.6% from 2015 to 2022. Growing zoonotic and foodborne diseases and greater livestock production are the key factors fueling the market growth. Increased competition for cultivated land and cost effective production are the m …
- 世界の対IED防衛市場動向2013-2023：トレンド、開発動向及び課題Technological Developments in the global Counter IED include: ■ The Vehicle Global Acceleration Mitigation (VGAM) and Vehicle Armored Floor Stabilization (VAFS) systems being developed by the UK. ■ Software to predict where IED attacks will take place and locate weapons caches. ■ The US Navy has developed a radio-frequency energy to detonate hidden IEDs. ■ US Navy developing the next generation co …
- 世界の金属製伸縮継手市場2015The Global Metal Expansion Joints Industry Report 2015 is a professional and in-depth study on the current state of the Metal Expansion Joints industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Metal Expansion Joints market analysis is provided for the international markets including development tren …
- テレビ会議サービスの世界市場：オンプレミス型テレビ会議サービス、ホスト型テレビ会議サービス、マネージド型テレビ会議サービスAbout VCS A few years ago, video conferencing was something SMEs hesitated to invest in because of high initial investment and huge TCO. Also, high-quality video calls required sufficient bandwidth, special video conferencing rooms, and expensive technology. Therefore, only large enterprises could justify these costs by reducing their travel expenses for initial sales meetings and presentation to …
- [Updated] 世界の水処理用化学薬品市場動向及び予測（～2018）Water treatment chemicals are primarily used for removing impurities from drinking as well as industrial water and wastewater. With the increasing scarcity of water resources globally, recycling and reuse of water has become very important. Water treatment chemicals are used effectively to remove harmful substances from water. Key chemicals that are used in the water treatment include corrosion in …
- 低血圧(Hypotension)：世界の治験レビュー（2015年上半期版）Hypotension Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Hypotension Global Clinical Trials Review, H1, 2015" provides data on the Hypotension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypotension. It includes an overview of the trial numbers and their recruitment status as per the site of …
- 航空機解体の世界市場2015-2019About Aircraft Dismantling The process of dismantling an aircraft at the end of its life as a combined airframe is known as parting out. Aircrafts may be parted out while they are still certified and still in service as the components in them are more valuable. As any product, an aircraft also depreciates in value over time. The value of the aircraft depends on a number of aspects such as increase …
- グローバルにおけるエネルギー貯蔵市場（予測、事業機会、動向、課題）With the growing demand for energy worldwide, the market for energy storage has witnessed a boom in recent years. Devices that can store energy for using at a later time have developed rapidly to meet the rising requirement for energy. Companies and governments worldwide are facilitating the growth of energy storage devices owing to their capability of storing electricity more effectively and effi …
- 世界のコリオリ流量計市場動向（2012-2016）TechNavio’s analysts forecast the Global Coriolis Flowmeter market to grow at a CAGR of 12.05 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for coriolis flowmeters across process industries. The Global Coriolis Flowmeter market has also been witnessing the development of industry-specific Coriolis flowmeters. However, lack of …
- 世界の実験室プラスチック製器具及びガラス製器具市場動向（2012-2016）TechNavio's analysts forecast the Global Laboratory Plasticware and Glassware market to grow at a CAGR of 5.17 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in research and development activities. The Global Laboratory Plasticware and Glassware market has also been witnessing the trend of increasing preference of plastic over glass. Ho …
- 燃料電池市場展望（～2017年）（Fuel Cell Market Outlook 2017）Fuel cells are an extremely resourceful technology with systems ranging from single watts up to megawatts. This created demand for this technology in various application areas including military, electronic devices, transportation, traffic signaling, security and remote monitoring etc. In addition, declining prices for fuel cells and advanced research and development activities are adding growth t …
- 局所薬物デリバリーの世界市場予測（～2024年）“The topical drug delivery market is projected to grow at a CAGR of 5.7% during the forecast period (2019–2024).”The topical drug delivery market is projected to reach USD 123.2 billion by 2024 from USD 93.2 billion in 2019, at a CAGR of 5.7%. The growth of the topical drug delivery market is driven mainly by the high prevalence of skin disease, rising incidences of eye diseases, high incidence of …
- Enbrel (Psoriasis)：市場予測と分析（～2022）Enbrel (Psoriasis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Enbrel (Psoriasis) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therap …
- M-Banking Markets and OpportunitiesMobile banking refers to a client-server system that is specifically designed for mobile devices, allowing banking customers to use handheld devices to access their accounts, pay bills, authorize fund transfers, or perform other activities. Like many other m-commerce services, mobile banking services can be challenging and no single company has all the expertise required to develop and deliver com …
- LiDAR（ライダー）製品の世界市場：航空用LiDAR、地上用LiDAR、レーザー・スキャナ、GPS、慣性測定装置（IMU）LiDAR, or light detection and ranging, is an emerging technology which is witnessing increased adoption across all the sectors. This is primarily due to the capability of this technology to produce highly precise images for 3D elevation modeling of terrains and urban establishments. Infrastructure projects are becoming more and more complex and require detailed planning and design. The LiDAR techn …
